Elekta Unity clinical users report seeing and treating cancer like never before at European radiation oncology conference
Record number of abstracts from the Elekta Unity community reflects solidifying support and continued confidence in modality
VIENNA – Elekta (EKTA-B.ST) today announced that Elekta Unity MR-Linac clinical users presented 93 abstracts highlighting how the high-field magnetic resonance guided radiation therapy (MRgRT) system’s continuous, rich and timely insights into motion and response are enabling precise, personalized radiation therapy. The abstracts were part of the scientific program at the European Society for Radiotherapy and Oncology (ESTRO) annual meeting, May 12-16 in Vienna, Austria.
Elekta Unity brings together diagnostic quality MR imaging with a linear accelerator, allowing clinicians to visualize tumors during treatment. Most recently, Elekta received CE mark and FDA clearance for Comprehensive Motion Management with True Tracking and automatic gating functionalities for Unity, which creates opportunities for condensed treatment courses, fewer side effects, and improved outcomes for cancer patients.
Dr. John Christodouleas, SVP of Medical Affairs & Clinical Research at Elekta, highlighted a new study on rectal cancer treatment using Elekta Unity. “Enhanced imaging on Elekta Unity enables treatment with less targeting uncertainty. This should translate into reduced side effects for rectal cancer patients but up until now, patient-reported outcomes (PROs) after treatment on Unity had not been reported. At ESTRO this year, Lois Daamen, MD, PhD, from the University Medical Center (UMC) Utrecht in the Netherlands, reported outcomes of rectal cancer treatment of 152 patients within the MOMENTUM Study. Overall, based on the PROs, treatment on Unity resulted in improved symptom management, and stabilized or improved quality of life outcomes after a one-year follow up.”
Another abstract highlighted by Dr. Christodouleas emphasizes the value of intrafraction drift correction included in the recent Comprehensive Motion Management release. “Rapid correction of intrafraction drift of a target realigns the beam with target’s new position, optimizing beam delivery without the time penalty of acquiring new images,” said Dr. Christodouleas. Madelon van den Dobbelsteen, from UMC Utrecht, presented a study that validates the performance of intrafraction drift correction and how it saves time compared to the department’s current workflow.
“It is becoming increasingly clear and gratifying that MRgRT is making a profound impact in the treatment of many disease sites, including the prostate, pancreas and rectum,” says Lionel Hadjadjeba, MD, President, Linac Solutions at Elekta. “The literature is immense, considering Unity was introduced just six years ago. The count is now up to 600 peer-reviewed articles published on Unity – an amazing milestone. Equally as impressive is the ongoing stream of innovations aimed at improving MRgRT even more, which at ESTRO 23 is reflected in the many abstracts on motion management. Elekta’s recent introduction of Comprehensive Motion Management – with its powerful algorithms to quantify movement and compensate for it automatically as it occurs – will change patient care.”
Learn more about the algorithms that allow clinicians to choose the right motion management strategy for every patient at https://www.elekta.com/products/radiation-therapy/unity/.
*Elekta Unity with Comprehensive Motion Management (CMM) has CE mark and U.S. FDA 510(k) clearance. Not available in all markets.
# # #
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time
Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.